2023 Fall Conference | C20 - Anti-amyloid Therapy Boot Camp

Date Saturday 10/28/23

Time 01:00 PM - 04:30 PM PDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Vijay K. Ramanan, MD, PhD

Topic(s) Aging, Dementia, and Behavioral Neurology

Learning Objectives Participants should be able to appraise major findings from recent clinical trials of anti-amyloid monoclonal antibody therapies in Alzheimer's disease; understand imaging and fluid biomarkers relevant for treatment eligibility and monitoring; identify proposed clinical criteria for appropriate use of anti-amyloid therapies in clinical practice; summarize mechanisms, risk factors, and safety monitoring for amyloid-related imaging abnormalities; and assess practice-level adaptations needed for emerging AD therapies.

This program is supported in part by educational grants from Eisai Inc. and Lilly.
The Academy was solely responsible, with no influence from the industry supporters, for selection of content, format, presenters, and moderators of this CME program, and the speakers have not been contacted or influenced in any way by the industry supporters with regard to this CME program.

CME Available 3.50 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement, Systems-based Practice

Program Level Intermediate

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student, Business Administrator

Teaching Styles Didactic, Audience Participation

Program Materials

Event Timeline
01:00 PM - 01:05 PM PDT	Introduction	Introduction Vijay K. Ramanan, MD, PhD
01:05 PM - 01:50 PM PDT	Speaker	Background and Outcomes on the Phase 3 Trials for Lecanemab and Donanemab Jared R. Brosch, MD
01:50 PM - 02:30 PM PDT	Speaker	Appropriate Use of Anti-Amyloid Monoclonal Antibodies in the Clinic Parichita Choudhury, MD
02:30 PM - 03:10 PM PDT	Speaker	Diagnosing and Managing ARIA with Anti-Amyloid Therapies Petrice M. Cogswell, MD, PhD
03:10 PM - 03:40 PM PDT	Speaker	Practice, System, and Payer Adaptations with Emerging Treatments Vijay K. Ramanan, MD, PhD
03:40 PM - 04:00 PM PDT	Speaker	Open Questions and Future Evolutions with Anti-Amyloid Therapies Vijay K. Ramanan, MD, PhD
04:00 PM - 04:30 PM PDT	Q&A	Questions and Answers Vijay K. Ramanan, MD, PhD, Parichita Choudhury, MD, Petrice M. Cogswell, MD, PhD, Jared R. Brosch, MD

Faculty Disclosures
Vijay K. Ramanan, MD, PhD	The institution of Dr. Ramanan has received research support from the National Institutes of Health. The institution of Dr. Ramanan has received research support from the Mangurian Foundation for Lewy Body Disease Research. The institution of Dr. Ramanan has received research support from as part of clinical trials sponsored by the Alzheimer's Association, Eisai, the Alzheimer's Treatment and Research Institute at USC, and Transposon Therapeutics, Inc.. The institution of Dr. Ramanan has received research support from Medscape. The institution of Dr. Ramanan has received research support from Expert Perspectives in Medicine. Dr. Ramanan has received personal compensation in the range of $500-$4,999 for serving as a Conference Speaker/Organizer (Honoraria) with AANI.
Parichita Choudhury, MD	The institution of Dr. Choudhury has received research support from Lewy Body Dementia Association. The institution of Dr. Choudhury has received research support from Arizona Alzheimer's Consortium.
Petrice M. Cogswell, MD, PhD	Dr. Cogswell has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Cogswell has received personal compensation in the range of $5,000-$9,999 for serving as a Medical education speaker with Eisai. Dr. Cogswell has received personal compensation in the range of $500-$4,999 for serving as a Medical education speaker with Kaplan.
Jared R. Brosch, MD	Dr. Brosch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Brosch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Brosch has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie. Dr. Brosch has stock in Monument Biosciences. The institution of Dr. Brosch has received research support from Alnylam Pharmaceuticals. The institution of Dr. Brosch has received research support from Athira Pharmaceuticals. The institution of Dr. Brosch has received research support from Biogen. The institution of Dr. Brosch has received research support from EISAI. The institution of Dr. Brosch has received research support from F. Hoffman La-Roche. The institution of Dr. Brosch has received research support from University of Southern California. The institution of Dr. Brosch has received research support from Washington University. Dr. Brosch has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��